Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells $36,242.10 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Oxana Beskrovnaya also recently made the following trade(s):

• On Wednesday, December 11th, Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock. The shares were sold at an average price of $28.12, for a total value of $65,632.08.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $13.79 on Thursday. The firm has a market cap of $1.40 billion, a P/E ratio of -3.87 and a beta of 1.11. Dyne Therapeutics, Inc. has a 1 year low of $13.07 and a 1 year high of $47.45. The firm’s 50 day moving average price is $17.41 and its 200 day moving average price is $28.03.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Friday, January 10th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, Robert W. Baird assumed coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.91.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $50,000. Neo Ivy Capital Management bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Dyne Therapeutics by 6.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company’s stock valued at $3,378,000 after acquiring an additional 9,029 shares in the last quarter. Voloridge Investment Management LLC bought a new position in Dyne Therapeutics during the 4th quarter valued at $2,804,000. Finally, Two Sigma Advisers LP grew its holdings in Dyne Therapeutics by 25.4% during the 4th quarter. Two Sigma Advisers LP now owns 76,100 shares of the company’s stock worth $1,793,000 after acquiring an additional 15,400 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.